key: cord-1019929-xdq5dx3a authors: Kelly, Colleen R.; Laine, Loren A.; Wu, Gary D. title: MONITORING FECAL MICROBIOTA TRANSPLANTATION PRACTICE IN A RAPIDLY EVOLVING HEALTH AND REGULATORY ENVIRONMENT date: 2020-08-22 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.08.039 sha: 9f9dd58e5cf1b01c0cee10a00c37962d124b8043 doc_id: 1019929 cord_uid: xdq5dx3a nan Fecal microbiota transplant (FMT) has demonstrated high efficacy in recurrent Clostridioides difficile infections (CDI) 1 . However, it remains an investigational therapy that may be used by practitioners without an investigational new drug (IND) application to treat CDI not responding to standard therapies under a policy of enforcement discretion by the U.S. Food and Drug Administration (FDA) 2 . This regulatory policy is driven, in part, by concerns that available safety data for FMT are inadequate, though there have been few serious short-term adverse events or infection transmissions reported in the literature to date 3 . Nevertheless, whether FMT may increase risk of conditions associated with alterations in gut microbiota such as obesity 4 , cardiovascular disease 5 , autoimmunity 6 or cancer 7 over the long term is unknown and remains a theoretical concern based on experimental laboratory models and limited clinical data. Published guidance from consensus conferences on donor identification and screening, optimal FMT practices and the safe operation of stool banks have aimed to establish bestpractices in FMT 8, 9 . While adverse events related to the procedure must be reported when FMT is being performed under FDA IND applications, the vast number of FMTs being done in the U.S. remain outside of the control of regulatory agencies and there is concern that infections or other complications of FMT may be under-reported. Under current FDA policy, it is the responsibility of clinicians and investigators to educate patients about potential risks related to the procedure, including infections and theoretical long-term risks of manipulating intestinal microbiota. No formal mechanism exists to prospectively collect short and long-term safety data, or to determine the impact of emerging pathogens and changing regulatory requirements, on FMT practice and outcomes. The FMT National Registry was established to fill these critical gaps in knowledge 10 . This NIH-funded and AGA-administered project, has enrolled 437 participants across 38 sites through July 1 st 2020. Early results from the registry confirm a high real-world effectiveness of the procedure and a remarkably low incidence of infections possibly related to FMT. Implementation of this study has resulted in access to a national network of FMT providers J o u r n a l P r e -p r o o f (including non-registry sites) that can provide timely feedback on the impact of real-world events on FMT practice. Herein, we provide a summary of surveys conducted by the registry investigators that have provided key insights into the impact of regulatory policies on sites providing FMT. In June 2019, the FDA issued a safety alert 11 on extended-spectrum beta-lactamase (ESBL)-producing E. coli transmission in 2 patients, one of whom died, after FMT for non-CDI indications. The donor for these FMTs was not screened for these organisms. This alert was accompanied by new requirements for IND holders, and recommendations to non-IND sites, that donors be screened for multi-drug-resistant organisms (MRDOs) and that patients be warned of these risks. During the months between this FDA safety alert and the paper describing details around the transmission events was published in the New England Journal of Medicine 12 , an August 2019 survey of registry sites was conducted to understand adherence to the new FDA donor screening protocols at sites not using OpenBiome as their exclusive source of stool. Though few respondents used material from sources other than OpenBiome, those using material from local stool banks or operating under IND reported that they were already in compliance with the FDA's recommendations. By contrast, those using patient-directed donors (e.g. friends or family members) reported that their sites had not screened donors about risk factors for colonization with MRDOs and were not testing donor stool for the specific organisms identified in the FDA safety alert. These sites either indicated plans to change donor screening and testing protocols to be in compliance with the FDA's recommendations, or to begin using material from OpenBiome exclusively due to the complexity of testing for MRDOs. More recently, in March 2020, the FDA issued a safety alert regarding transmission of enteropathogenic E. coli (EPEC) and Shiga-toxin producing E. coli (STEC), via donor stool sourced from OpenBiome 13 . AGA was able to rapidly communicate details regarding these infections to registry sites as well as the society membership. The emergence of the novel coronavirus, SARS-CoV-2, and concern about the potential for transmission through feces prompted another FDA safety alert on FMT and donor screening, announced in March 2020 14 . This safety alert recommended that donor stool obtained after December 1, 2019 be discarded or tested for SARS-CoV-2 before being used to treat patients. In June, Finch Therapeutics announced positive results from its placebo-controlled Phase 2 of an investigational oral gut microbiota product for the prevention of recurrent CDI 18 . Rebiotix recently announced completion of a phase 3 trial of its own donor-derived microbiota product for treatment of CDI 19 , and results from and another phase 3 trial of an orally-J o u r n a l P r e -p r o o f administered microbiome therapeutic agent developed by Seres Health for treatment of CDI 20 are due to be released later this year. It is hoped that approval of these products and other "purified" microbial preparations will reduce concerns around donor screening and infection transmission, expanding treatment options for patients, and facilitating research around FMT for other indications. While, in time, these products may supplant donor fecal material, it is likely that conventional full-spectrum donor-derived FMT will continue to be performed in a significant number of patients, particularly those with severe or fulminant CDI or for investigational applications such as inflammatory bowel disease, autism spectrum disorders or metabolic syndrome. The FMT National Registry will continue to be an important source of long-term data on the effects of dramatic manipulation of the gut microbiome and provide rapid real-time insights into the impact of FMT developments and policy changes on clinical practice. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies Systematic Review: Adverse Events of Fecal Microbiota Transplantation The Human Microbiome and Obesity: Moving beyond Associations Gut Microbiota in Cardiovascular Health and Disease Impacts of microbiome metabolites on immune regulation and autoimmunity The microbiome and cancer International consensus conference on stool banking for faecal microbiota transplantation in clinical practice Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice The AGA's Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics Information Pertaining to Additional Safety Protections Regarding Use of Fecal Microbiota for Transplantation -Screening and Testing of Stool Donors for Multi-drug Resistant Organisms Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant Adminstration USFaD. afety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19 Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic SARS-CoV-2 productively infects human gut enterocytes Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection Rebiotix and Ferring announce world's first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660 Ahead of Phase 3 ECOSPOR III Study Read-Out